Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares

2 hours ago 4

Jonathan Ponciano, The Motley Fool

Sun, May 17, 2026 astatine 2:13 PM CDT 4 min read

On May 15, 2026, HighVista Strategies disclosed it sold 70,503 shares of Maze Therapeutics (NASDAQ:MAZE) successful Q1 2026, an estimated $3.11 cardinal commercialized based connected quarterly mean pricing.

What happened

According to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, HighVista Strategies reduced its presumption successful Maze Therapeutics by 70,503 shares during the archetypal quarter. The estimated worth of the shares sold was $3.11 million, based connected the mean closing terms for the quarter. The money ended the play with 99,850 shares, worthy $2.98 million.

What other to cognize

This was a sale, leaving Maze Therapeutics astatine 0.82% of reported AUM.
Top holdings aft the filing:
- NYSEMKT:DBC: $30.61 cardinal (8.5% of AUM)
- NASDAQ:ABVX: $12.61 cardinal (3.5% of AUM)
- NASDAQ:PRAX: $8.48 cardinal (2.3% of AUM)
- NASDAQ:COGT: $7.58 cardinal (2.1% of AUM)
- NASDAQ:SYRE: $7.38 cardinal (2.0% of AUM)
As of May 14, 2026, shares of Maze Therapeutics were priced astatine $26.43, up astir 180% implicit the past twelvemonth and outperforming the S&P 500’s astir 25% summation successful the aforesaid period.

Company Overview

Metric

Value

Market Capitalization	$1.40 billion
Price (as of marketplace adjacent 2026-05-14)	$26.43
Net Income (TTM)	($131.1 million)

Company Snapshot

Maze Therapeutics develops tiny molecule precision medicines targeting renal, cardiovascular, metabolic diseases, and obesity, with pb programs MZE829 (APOL1 kidney disease, Phase II) and MZE782 (chronic kidney disease, Phase I).
The steadfast operates a clinical-stage biopharmaceutical concern model.
It develops therapeutics for renal, cardiovascular, metabolic diseases, and obesity successful the United States.

Maze Therapeutics, Inc. is simply a clinical-stage biotechnology institution based successful South San Francisco, California, focused connected processing precision medicines for superior renal and metabolic conditions. The institution leverages proprietary familial insights to beforehand a pipeline of tiny molecule therapies, aiming to code unmet aesculapian needs successful kidney and related diseases. With ongoing objective trials and a increasing portfolio, Maze Therapeutics seeks to found a competitory presumption successful the biopharmaceutical assemblage done innovation and targeted cause development.

What this transaction means for investors

This merchantability looks little similar a classical biotech portfolio rebalance aft a immense run. Maze Therapeutics shares person climbed astir 180% implicit the past year, and HighVista appears to person locked successful immoderate gains portion inactive maintaining vulnerability to the story.

The absorbing portion is that the trim comes aft Maze reported encouraging Phase 2 information for MZE829, its pb kidney illness candidate. In March, the institution said patients successful its HORIZON proceedings saw a 35.6% simplification successful proteinuria astatine week 12, with adjacent stronger results successful definite focal segmental glomerulosclerosis patients. Still, the banal crashed implicit 30% aft the news, with investors worrying the cause whitethorn not enactment arsenic good arsenic a rival offering. Either way, Maze present plans to determination the cause into a pivotal proceedings successful 2027.

For semipermanent investors, the cardinal question is whether MZE829’s aboriginal kidney illness information tin yet construe into a commercially meaningful therapy. The subject is getting stronger, but aft specified a crisp banal move, expectations are climbing conscionable arsenic fast.

Read Entire Article